Therefore, identifying effective strategies to stop the HP-mediated induction and progression of GC, deepening our understanding of GC pathogenesis, and identifying novel therapeutic and preventive targets are essential for improving GC treatment outcomes. The gene discussed is HP; the disease is gastric cancer.